CN1477958A - 组合物及方法 - Google Patents
组合物及方法 Download PDFInfo
- Publication number
- CN1477958A CN1477958A CNA018181880A CN01818188A CN1477958A CN 1477958 A CN1477958 A CN 1477958A CN A018181880 A CNA018181880 A CN A018181880A CN 01818188 A CN01818188 A CN 01818188A CN 1477958 A CN1477958 A CN 1477958A
- Authority
- CN
- China
- Prior art keywords
- cognitive function
- decline
- day
- compositions
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Birds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
一种组合物,该组合物包含一种其量足以预防或抑止或逆转认知功能下降的抗氧化剂或其混合物。
Description
发明背景
随着人类年龄的增长,其智力似乎有所下降。这普遍适用于人类,而且与具体的健康状况(如早老性痴呆)以及其它已知的影响智能的具体疾病无关。记忆力没有以前好。学会某些技能需要花费更长的时间。这类智力上的变化某些时候与“年老”相伴或被称为“年老”。最近该综合性领域被称为认知功能下降,或更专业地被称为下降的智能。
老年人的这种认知功能下降现在可以使用特定的组分来预防、抑止或治疗。这些组分可以通过饮食或单独的口服摄入。
发明概述
本发明提供了一种组合物,该组合物包含一种其量足以a.预防或b.抑止或c.逆转认知功能下降的抗氧化剂或其混合物。
另一方面提供一种通过摄入这种组合物来预防、抑止或逆转认知功能下降的方法。
发明详述
人类认知功能的下降最早可在50左右岁开始发生,但通常在60或70岁时变得明显。
用于本申请时,能实现发明目的的组分是抗氧化剂或其混合物。抗氧化剂是一种抑止自由基的物质。此种物质的例子有β-胡萝卜素,硒,辅酶Q10(泛醌),黄体素,生育三烯酚,大豆异黄酮,S-腺苷蛋氨酸,谷胱苷肽,牛磺酸,N-乙酰半胱氨酸,维生素E,维生素C,α-硫辛酸,1-肉毒碱等。维生素E可以以生育酚或生育酚混合物以及其各种衍生物(如酯型的维生素E醋酸酯、琥珀酸酯、棕榈酸酯等)的形式摄入。优选α型,也可包括β、γ和δ型。优选d型,但外消旋混合物也可以接受。摄入以后的这些类型和衍生物以类似于维生素E的活性发挥功能。维生素C可以以抗坏血酸及其各种衍生物(如钙磷酸盐、胆甾醇基盐、2-一磷酸盐等)的形式摄入,摄入人体以后以类似于维生素C的活性发挥功能。它们可以以任何形态存在,如液态、半固态、固态和热稳定态。α-硫辛酸可以以α-硫辛酸或美国专利5621117中提到的硫辛酸酯衍生物、或其外消旋混合物、盐、酯或酰胺的形式摄入。可以使用L-肉毒碱以及肉毒碱的各种衍生物(如盐,比如氢氯化物、富马酸盐、琥珀酸盐)以及乙酰化的肉毒碱等。
人体摄入的量以活性物质来计算,也就是说,以特定物质来衡量。所用的最小量不至于产生毒性。维生素E的最小摄入量约为50或100或150mg/天。通常可以使用不超过2,000mg/天,或者理想的是约1,000或约750mg/天。维生素C的最小摄入量通常为约150、约200或约250mg/天。最大摄入量通常不超过约1,000mg/天,但可以更低,如约900或约750mg/天。α疏辛酸的摄入量至多为约10或20mg/kg体重/天。最小摄入量为约0.5或1mg/kg体重/天。L-肉毒碱的摄入方式与α硫辛酸相同。α硫辛酸和1-肉毒碱的摄入量可以更高,但没有观察到明显不同的效果。
另外的抗氧化剂及其用量以mg/kg体重/天计。
β-胡萝卜素的使用量可为至少约0.02mg/kg体重/天,1-15ppm。
硒的使用量可为约0.02mg/kg体重/天,至多5ppm。
黄体素的使用量可为至少约5ppm mg/kg体重/天。
生育三烯酚的使用量可为至少约0.5mg/kg体重/天。
辅酶Q10的使用量可为至少约0.5mg/kg体重/天。
S-腺苷蛋氨酸的使用量可为至少约1.0mg/kg体重/天。
牛磺酸的使用量可为至少约10mg/kg体重/天。
大豆异黄酮的使用量可为至少约0.5mg/kg体重/天。
N-乙酰半胱氨酸的使用量可为至少约1.0mg/kg体重/天。
谷胱苷肽的使用量可为至少约1.0g/kg体重/天。
银杏的使用量可为至少1.0m/kg体重/天。
可以以类似于维生素的典型的“每天一次”的剂量来摄入这些量。可以以例如片剂、胶囊、囊片的形式,或任何用于人体摄入的以液体为载体的形式来摄入。此外,为了方便或别的原因,每日剂量可以分成二、三或四个剂量单位。此外,也可以在食物中摄取,如快餐、谷类等。
实施例1
一个成人从45岁起,每日食用可以提供750mg维生素E、250mg维生素C、200mg硫辛酸和400mg 1-肉毒碱的补品或食物,持续5年。到50岁时,没有出现任何智力下降的迹象,如定向力障碍、记忆力下降、学习能力减弱、或独立应对其周围生活环境的能力下降,这些可以通过实物(或非实物)测试来分级,如Folstein的小型智力水平测验(MME),来自Wechsler记忆力标准(WMS)的逻辑记忆和视觉再现测试,有关日常生活活性的Katz标准,有关日常生活器具活性的Lawton标准,Pfeiffer的智力水平调查,或由其自身、给予照料者或提供健康照料者来诊断的其它相关测试。
实施例2
一个有智力下降迹象的成人,如定向力障碍、记忆力下降、学习能力减弱、或独立应对其周围生活环境的能力下降,这些可以通过实物(或非实物)测试来分级,如Folstein的小型智力水平测验(MME),来自Wechsler记忆力标准(WMS)的逻辑记忆和视觉再现测试,有关日常生活活性的Katz标准,有关日常生活器具活性的Lawton标准,Pfeiffer的智力水平调查,或由其自身、给予照料者或提供健康照料者来诊断的其它相关测试,让其每日摄入可以提供750mg维生素E、250mg/维生素C、200mg硫辛酸和400mg 1-肉毒碱的日常食物或补品,持续1年。服用1年以后,上述迹象显著降低。
实施例3
一个有智力下降迹象的成人,如定向力障碍、记忆力下降、学习能力减弱、或独立应对其周围生活环境的能力下降,这些可以通过实物(或非实物)测试来分级,如Folstein的小型智力水平测验(MME),来自Wechsler记忆力标准(WMS)的逻辑记忆和视觉再现测试,有关日常生活活性的Katz标准,有关日常生活器具活性的Lawton标准,Pfeiffer的智力水平调查,或由其自身、给予照料者或提供健康照料者来诊断的其它相关测试,让其每日摄入可以提供750mg维生素E、250mg/维生素C、200mg硫辛酸和400mg 1-肉毒碱的日常食物或补品,持续2年。服用2年以后,上述迹象基本消失。
Claims (10)
1.一种组合物,该组合物包含一种其量足以
a.预防,或
b.抑止,或
c.逆转
认知功能下降的抗氧化剂或其混合物。
2.如权利要求1所述的组合物,其中认知功能的下降被预防。
3.如权利要求1所述的组合物,其中认知功能的下降被抑止。
4.如权利要求1所述的组合物,其中认知功能的下降被逆转。
5.如权利要求1所述的组合物,其中维生素E至少约50mg/天,维生素C至少约150mg/天,1-肉毒碱至少约0.5mg/kg体重/天,α硫辛酸至少约0.5mg/kg体重/天。
6.一种预防或抑止或逆转人的认知功能下降的方法,包括给该人服用权利要求1的组合物。
7.如权利要求6所述的方法,其中该人需要进行所述的服用。
8.如权利要求6所述的方法,其中认知功能的下降被预防。
9.如权利要求6所述的方法,其中认知功能的下降被抑止。
10.如权利要求6所述的方法,其中认知功能的下降被逆转。
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24451100P | 2000-10-31 | 2000-10-31 | |
US60/244,511 | 2000-10-31 | ||
US25344600P | 2000-11-28 | 2000-11-28 | |
US25344700P | 2000-11-28 | 2000-11-28 | |
US60/253,447 | 2000-11-28 | ||
US60/253,446 | 2000-11-28 | ||
US09/922,633 | 2001-08-06 | ||
US09/922,633 US20020052402A1 (en) | 2000-10-31 | 2001-08-06 | Composition and method |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1477958A true CN1477958A (zh) | 2004-02-25 |
Family
ID=27500158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA018181880A Pending CN1477958A (zh) | 2000-10-31 | 2001-10-30 | 组合物及方法 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1339404A2 (zh) |
JP (1) | JP2004514686A (zh) |
CN (1) | CN1477958A (zh) |
AU (1) | AU2002232616A1 (zh) |
CA (1) | CA2427470A1 (zh) |
WO (1) | WO2002043666A2 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007065314A1 (fr) * | 2005-12-08 | 2007-06-14 | Pficker Pharmaceuticals, Ltd. | Composition pour le traitement d'une hepatopathie virale |
CN101045048B (zh) * | 2006-03-27 | 2011-05-18 | 中国科学院上海生命科学研究院 | 线粒体营养素组合物的应用 |
CN101287460B (zh) * | 2005-08-17 | 2012-04-25 | 希尔氏宠物营养品公司 | 预防和治疗肾病的组合物 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005185188A (ja) * | 2003-12-25 | 2005-07-14 | Nichirei Corp | アセロラ処理物およびl−カルニチン含有組成物 |
CN1917779B (zh) * | 2004-01-28 | 2010-06-16 | 雀巢技术公司 | 用于改善皮肤状况和防止皮肤病的营养组合物 |
AU2005309502B2 (en) * | 2004-11-24 | 2011-11-17 | Hill's Pet Nutrition, Inc. | Methods for increasing the immune response in an animal |
BRPI0518580A2 (pt) * | 2004-11-24 | 2008-11-25 | Hills Pet Nutrition Inc | mÉtodo para melhorar a depuraÇço hepÁtica de substÂncias xenobiàticas em um animal, kit adequado para alimentar Ácido lipàico a um animal, meio para comunicar informaÇço, composiÇço, e, uso da composiÇço que compreende Ácido lipàico |
US20090176864A1 (en) * | 2004-11-24 | 2009-07-09 | Hill's Pet Nutrition, Inc. | Methods For Improving Hepatic and Immune Function In An Animal |
EP2123263A1 (en) * | 2007-02-14 | 2009-11-25 | Tohoku University | Composition and method for suppressing lipid peroxidation in erythrocytes |
US20120288608A1 (en) * | 2009-07-14 | 2012-11-15 | Hill's Pet Nutrition, Inc. | Pet food compositions including a sustained-release lipoic acid and methods of manufacture and use thereof |
EP2508179A1 (en) | 2011-04-05 | 2012-10-10 | Lonza Ltd. | Use of L-Carnitine, salts and derivatives thereof for reducing or preventing fatigue and improving cognitive function |
JP2014532032A (ja) | 2011-04-05 | 2014-12-04 | ロンザ・リミテッド | 疲労を減少させるためまたは予防するためおよび認知機能を改善するためのl−カルニチン、その塩および誘導体の使用 |
NL2024431B1 (en) | 2019-12-11 | 2021-09-07 | Sulfateq Bv | Compounds for treatment of alzheimer’s disease |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06199690A (ja) * | 1992-03-06 | 1994-07-19 | Yunie:Kk | 脳代謝促進・脳機能改善剤 |
DE4343592C2 (de) * | 1993-12-21 | 1998-04-16 | Asta Medica Ag | Verwendung von R-(+)-alpha-Liponsäure und dessen Metaboliten in Form der freien Säure oder als Salze oder Ester oder Amide zur Behandlung von Glukosestoffwechselstörungen des zentralen Nervensystems |
FR2721516B1 (fr) * | 1994-06-27 | 1996-09-13 | Inst Rech Biolog Sa | Nouvelles utilisations d'un complexe à base de phospholipides cérébraux en thérapeutique et dans l'alimentation. |
US5977162A (en) * | 1996-09-16 | 1999-11-02 | Seidman; Michael D. | Therapeutic treatment for auditory function |
IT1302307B1 (it) * | 1998-09-01 | 2000-09-05 | Sigma Tau Healthscience Spa | Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil |
WO2000054754A2 (en) * | 1999-03-16 | 2000-09-21 | Merck Patent Gmbh | Composition comprising isoquercetin and ascorbic acid in a sustained release form |
AU3913800A (en) * | 1999-03-26 | 2000-10-16 | Lipogenics, Inc. | Novel antioxidant formulations and methods for using them |
DE19920316A1 (de) * | 1999-05-03 | 1999-12-09 | Heinz Kiefer | Arzneimittel als Antioxidans mit einer Vitamin-Spurenelement-Kombination zur Förderung der Funktionstüchtigkeit der Zellen |
US6646013B1 (en) * | 1999-06-15 | 2003-11-11 | Nutri-Logics | Nutrient formulations for disease reduction |
US6335361B1 (en) * | 1999-11-03 | 2002-01-01 | Juvenon Inc. | Method of treating benign forgetfulness |
JP2003529347A (ja) * | 2000-01-25 | 2003-10-07 | ジュヴェノン インコーポレイテッド | 高齢ペット用の栄養補給食品 |
HU227182B1 (en) * | 2000-03-06 | 2010-09-28 | Andras Javor | Lecitin-ascorbic acid combination |
-
2001
- 2001-10-30 AU AU2002232616A patent/AU2002232616A1/en not_active Abandoned
- 2001-10-30 EP EP01992146A patent/EP1339404A2/en not_active Withdrawn
- 2001-10-30 WO PCT/US2001/048665 patent/WO2002043666A2/en not_active Application Discontinuation
- 2001-10-30 CA CA002427470A patent/CA2427470A1/en not_active Abandoned
- 2001-10-30 JP JP2002545645A patent/JP2004514686A/ja active Pending
- 2001-10-30 CN CNA018181880A patent/CN1477958A/zh active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101287460B (zh) * | 2005-08-17 | 2012-04-25 | 希尔氏宠物营养品公司 | 预防和治疗肾病的组合物 |
WO2007065314A1 (fr) * | 2005-12-08 | 2007-06-14 | Pficker Pharmaceuticals, Ltd. | Composition pour le traitement d'une hepatopathie virale |
CN101045048B (zh) * | 2006-03-27 | 2011-05-18 | 中国科学院上海生命科学研究院 | 线粒体营养素组合物的应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2002043666A3 (en) | 2003-01-30 |
CA2427470A1 (en) | 2002-06-06 |
WO2002043666A2 (en) | 2002-06-06 |
EP1339404A2 (en) | 2003-09-03 |
AU2002232616A1 (en) | 2002-06-11 |
JP2004514686A (ja) | 2004-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1477958A (zh) | 组合物及方法 | |
EP1339292B2 (en) | Companion pet diet | |
AU2007216836B2 (en) | Composition and method | |
EP1331855B1 (en) | Aged companion pet diet | |
US8110600B2 (en) | Formulation and delivery method to enhance antioxidant potency of vitamin E | |
US20020172721A1 (en) | Vitamin formulation for cardiovascular health | |
US20020076469A1 (en) | Composition and method | |
WO2002007768A1 (en) | Dietary supplement compositions | |
US20110274791A1 (en) | Multivitamin/mineral formulation to combat the effects of environmental stress; improved immunity and improve energy while addressing vitamin and mineral deficiencies without the negative side effects of a mega dose nutritional supplement | |
EP1036510B1 (en) | Vitamin formulation for cardiovascular health | |
US20020052402A1 (en) | Composition and method | |
US20110177010A1 (en) | Vitamin preparation | |
ZA200303749B (en) | Compositions containing an antioxidant such as alpha lipoic acid, carnitine, Vitamin C or Vitamin E for preventing or inhibiting loss of cognitive function. | |
ZA200303746B (en) | Aged companion pet diet. | |
US10342824B2 (en) | Supplement for treating side effects of medications which cause metabolic acidosis | |
AU2002241634A1 (en) | Aged companion pet diet | |
JP2010142237A (ja) | 組成物及び方法 | |
AU2007216796A1 (en) | Composition and method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
AD01 | Patent right deemed abandoned | ||
C20 | Patent right or utility model deemed to be abandoned or is abandoned |